Organogenesis Statistics
Share Statistics
Organogenesis has 125.73M shares outstanding. The number of shares has increased by -4.73% in one year.
| Shares Outstanding | 125.73M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -5.17% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 67.50M |
| Failed to Deliver (FTD) Shares | 91 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 11.00M, so 8.75% of the outstanding shares have been sold short.
| Short Interest | 11.00M |
| Short % of Shares Out | 8.75% |
| Short % of Float | 16.3% |
| Short Ratio (days to cover) | 9.69 |
Valuation Ratios
The PE ratio is 108.54 and the forward PE ratio is -86.25. Organogenesis 's PEG ratio is 0.22.
| PE Ratio | 108.54 |
| Forward PE | -86.25 |
| PS Ratio | 1.24 |
| Forward PS | 0.7 |
| PB Ratio | 1.93 |
| P/FCF Ratio | 81.91 |
| PEG Ratio | 0.22 |
Enterprise Valuation
Organogenesis Inc. has an Enterprise Value (EV) of 551.75M.
| EV / Earnings | 111.58 |
| EV / Sales | 1.27 |
| EV / EBITDA | 15.31 |
| EV / EBIT | 44.05 |
| EV / FCF | 84.2 |
Financial Position
The company has a current ratio of 2.8, with a Debt / Equity ratio of 0.24.
| Current Ratio | 2.8 |
| Quick Ratio | 2.44 |
| Debt / Equity | 0.24 |
| Total Debt / Capitalization | 19.2 |
| Cash Flow / Debt | 0.47 |
| Interest Coverage | 5.72 |
Financial Efficiency
Return on equity (ROE) is 0.02% and return on capital (ROIC) is 1.5%.
| Return on Equity (ROE) | 0.02% |
| Return on Assets (ROA) | 0.01% |
| Return on Capital (ROIC) | 1.5% |
| Revenue Per Employee | 502.48K |
| Profits Per Employee | 5.74K |
| Employee Count | 862 |
| Asset Turnover | 0.94 |
| Inventory Turnover | 3.77 |
Taxes
| Income Tax | 5.45M |
| Effective Tax Rate | 0.52 |
Stock Price Statistics
The stock price has increased by -23.95% in the last 52 weeks. The beta is 1.6, so Organogenesis 's price volatility has been higher than the market average.
| Beta | 1.6 |
| 52-Week Price Change | -23.95% |
| 50-Day Moving Average | 3.46 |
| 200-Day Moving Average | 2.95 |
| Relative Strength Index (RSI) | 34.74 |
| Average Volume (20 Days) | 713.14K |
Income Statement
In the last 12 months, Organogenesis had revenue of 433.14M and earned 4.95M in profits. Earnings per share was 0.04.
| Revenue | 433.14M |
| Gross Profit | 326.66M |
| Operating Income | 12.53M |
| Net Income | 4.95M |
| EBITDA | 36.03M |
| EBIT | 12.53M |
| Earnings Per Share (EPS) | 0.04 |
Balance Sheet
The company has 104.34M in cash and 119.35M in debt, giving a net cash position of -15.01M.
| Cash & Cash Equivalents | 104.34M |
| Total Debt | 119.35M |
| Net Cash | -15.01M |
| Retained Earnings | -40.97M |
| Total Assets | 446.30M |
| Working Capital | 161.23M |
Cash Flow
In the last 12 months, operating cash flow was 30.92M and capital expenditures -24.36M, giving a free cash flow of 6.55M.
| Operating Cash Flow | 30.92M |
| Capital Expenditures | -24.36M |
| Free Cash Flow | 6.55M |
| FCF Per Share | 0.05 |
Margins
Gross margin is 75.42%, with operating and profit margins of 2.89% and 1.14%.
| Gross Margin | 75.42% |
| Operating Margin | 2.89% |
| Pretax Margin | 2.4% |
| Profit Margin | 1.14% |
| EBITDA Margin | 8.32% |
| EBIT Margin | 2.89% |
| FCF Margin | 1.51% |
Dividends & Yields
ORGO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 1.38% |
| FCF Yield | 1.8% |
Analyst Forecast
The average price target for ORGO is $5, which is 73% higher than the current price. The consensus rating is "Buy".
| Price Target | $5 |
| Price Target Difference | 73% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | 2.6 |
| Piotroski F-Score | 6 |